Novo

Last month, Teva Pharmaceuticals, has announced the launch of a corporate venture capital fund. The new fund will be headed by Dr. Aaron Schwarz, a Teva veteran, and will seek investment in biotech companies. In doing so, Teva joins a list of leading pharmaceuticals that increasingly shift their attention externally as a way to stimulate their product pipeline.